# Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

> **NCT04830579** · PHASE1 · UNKNOWN · sponsor: **Pharmtechnology LLC** · enrollment: 34 (estimated)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Etoricoxib film-coated tablet 120 mg
- **DRUG:** Arcoxia® film-coated tablet 120 mg

## Key facts

- **NCT ID:** NCT04830579
- **Lead sponsor:** Pharmtechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-10
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2021-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830579, "Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04830579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*